Table of Contents January 2006 On the Cover Competitive intelligence: The eyes and ears of the industry Shrinking pipelines, increased regulatory scrutiny, and the emergence of clinical-trial registries are just a few of the factors that are creating a tougher environment for industry players and prompting a need for companies to have a stronger competitive intelligence framework. CI teams are evolving to meet the industry’s current and future challenges. Features Alzheimer’s disease: Untangling the brain’s mystery Despite advances over the last decade in treating Alzheimer’s disease, there is still a need for a way to diagnose the disease earlier and for therapies that slow the course of the disease. Products in late-stage development offer some hope. HBA unleashes the power of being Becoming an Agent of Change — Focus of the 2005 Leadership Conference The new detail: Creating value Preserving access for sales representatives with physicians and creating win-win relationships are two major challenges facing the industry, but opportunities exist for creative people committed to healthcare and the value of medicine. Pamela Williamson Joyce — Sense and sensibility With a wide and deep understanding of the inner sanctum of numerous areas in the life sciences, Pamela Williamson Joyce has been able to bring both inventiveness and clear-headed thinking to Serono’s regulatory practice. In Every Issue Letter from the Editor For Art’s Sake A creative review by the experts PharmaOutlet Scott Hagedorn talks about how to harness the power of blogs. PharmaTrax Sales, marketing, and R&D trends from industry analysts What’s New New healthcare-related products, services, and companies E-Media New electronic and Web-based applications, sites, and technologies On The Calendar Industry events Talent Pool Executive appointments and promotions Steven Levy says it’s essential for companies to have global CI capabilities. Dr. Eliot Cole explains that rep value starts with the right training. Pamela Williamson Joyce talks about the industry’s regulatory challenges.
